Understanding these endocytic pathways provides valuable insights into the potential of syndecans as biomarkers and therapeutic targets for early intervention in Alzheimer’s disease and other related neurodegenerative disorders. Here, SDC1 is linked to early-onset autosomal dominant Alzheimer disease.